Crossfund Sicav-Crossinvest Healthcare Fund A CHF

Reference Data

ISIN LU1334634539
Valor Number 30671963
Bloomberg Global ID
Fund Name Crossfund Sicav-Crossinvest Healthcare Fund A CHF
Fund Provider Crossinvest SA Lugano, Switzerland
Phone: +41 91 911 88 88
E-Mail: info@crossinvest.ch
Web: www.crossinvest.ch
Fund Provider Crossinvest SA
Representative in Switzerland FundPartner Solutions (Suisse) SA
Genève 75
Distributor(s) FundPartner Solutions (Suisse) SA
Genève 3
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The investment objective of the Sub‐Fund is to achieve a long term capital appreciation by pursuing sector focus exposure opportunities in companies involved in health and personal care. These companies could participate in the research, clinical development or commercialization of medicines, equipment or services for disease treatment or life style improvement. The investment focus will be on industry leaders that offer premium growth and/or profitability prospects, pipeline and valuation upside. The Sub‐Fund is actively managed. The Sub‐Fund has no benchmark index and is not managed in reference to a benchmark index.
Peculiarities

Fund Prices

Current Price * 120.65 CHF 31.03.2025
Previous Price * 120.88 CHF 28.03.2025
52 Week High * 143.97 CHF 30.08.2024
52 Week Low * 118.35 CHF 30.12.2024
NAV * 120.65 CHF 31.03.2025
Issue Price * 120.65 CHF 31.03.2025
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 68,193,912
Unit/Share Assets *** 12,354,664
Trading Information SIX

Performance

YTD Performance +1.79% 31.12.2024
31.03.2025
1 month -4.14% 28.02.2025
31.03.2025
3 months +1.79% 31.12.2024
31.03.2025
6 months -12.30% 30.09.2024
31.03.2025
1 year -10.11% 02.04.2024
31.03.2025
2 years -5.63% 31.03.2023
31.03.2025
3 years -15.25% 31.03.2022
31.03.2025
5 years +12.01% 31.03.2020
31.03.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Novo Nordisk AS Class B 5.43%
Eli Lilly and Co 4.63%
UnitedHealth Group Inc 3.71%
AstraZeneca PLC 3.70%
Thermo Fisher Scientific Inc 3.09%
Roche Holding AG 3.09%
Danaher Corp 3.04%
Sanofi SA 2.96%
Novartis AG Registered Shares 2.82%
Abbott Laboratories 2.77%
Last data update 30.11.2024

Cost / Risk

TER
TER date
Performance Fee *** 15.00%
PTR
Max. Management Fee *** 1.50%
Ongoing Charges ***
SRRI ***
SRRI date *** 28.02.2025

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)